Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)

This publication has 28 references indexed in Scilit:

• Treatment of Acute Lymphoblastic Leukemia
  New England Journal of Medicine, 2006
• Therapy of low‐risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?
  Pediatric Blood & Cancer, 2005
• Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial
  British Journal of Haematology, 2005
• Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience
  Leukemia, 2005
• Childhood Leukemia — New Advances and Challenges
  New England Journal of Medicine, 2004
• Dexamethasone‐associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin
  Cancer, 2003
• Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
  Blood, 2003
• Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia
  Pediatric Research, 2002
• Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
  Cancer, 2000
• High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
  Journal of Clinical Oncology, 1996